EN

ENZYCHEM LIFESCIENCES CORPORATION

Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.

183490 | KO

Overview

Corporate Details

ISIN(s):
KR7183490002
LEI:
Country:
South Korea
Address:
충청북도 제천시 바이오밸리로 59, 제천시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Enzychem Lifesciences Corporation is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics for inflammatory diseases, oncology, and severe respiratory conditions. The company's primary focus is its lead candidate, EC-18 (Mosedipimod), an oral immunomodulator designed to target fundamental inflammation pathways. Its development pipeline addresses significant unmet medical needs, including chemoradiation-induced oral mucositis (CRIOM), chemotherapy-induced neutropenia (CIN), and acute radiation syndrome (ARS). In addition to its research and development in new drugs, the company also develops and manufactures Active Pharmaceutical Ingredients (APIs).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-20 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약체결결정)
Korean 33.2 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.9 MB
2025-06-10 00:00
Transaction in Own Shares
신탁계약해지결과보고서
Korean 21.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.7 MB
2025-04-21 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 93.4 KB
2025-04-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 95.3 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 26.9 KB
2025-03-24 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 95.3 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 26.3 KB
2025-03-18 00:00
Annual Report
사업보고서 (2024.12)
Korean 2.5 MB
2025-03-12 00:00
Major Shareholding Notification
신탁계약에의한취득상황보고서
Korean 49.5 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 264.6 KB
2025-03-07 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 216.5 KB
2025-03-06 00:00
Earnings Release
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 18.8 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 15.3 KB

Automate Your Workflow. Get a real-time feed of all ENZYCHEM LIFESCIENCES CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ENZYCHEM LIFESCIENCES CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ENZYCHEM LIFESCIENCES CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

GENELUX Corp Logo
Developing oncolytic viral immunotherapies for difficult-to-treat cancers using a vaccinia virus.
United States of America
GNLX
GENEMATRIX INC. Logo
Develops multiplex PCR diagnostics and new drugs for infectious diseases like HPV and tuberculosis.
South Korea
109820
Genenta Science S.p.A. Logo
Develops cell & gene therapies using engineered stem cells to treat solid tumors.
United States of America
GNTA
GeneOne Life Science, Inc. Logo
Develops nucleic acid vaccines & therapies for infectious diseases, cancer & autoimmune disorders.
South Korea
011000
Generation Bio Co. Logo
Developing siRNA genetic medicines via targeted nanoparticles for autoimmune diseases.
United States of America
GBIO
Genetic Analysis AS Logo
Develops microbiome diagnostics to detect gut dysbiosis for clinical and pharma partners.
Norway
GEAN
GENFIT Logo
Biopharma developing therapies & diagnostics for rare, life-threatening liver diseases.
France
GNFT
Genfit S.A. Logo
Biopharma developing therapeutics and diagnostics for rare and life-threatening liver diseases.
United States of America
GNFT
GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. Logo
Develops and manufactures pharmaceuticals for rare diseases and unmet health needs globally.
Türkiye
GENIL
Genmab Logo
Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.
Denmark
GMAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.